CD148 Mouse anti-Human, Alexa Fluor 647, Clone: A3, BD
Mouse Monoclonal Antibody
Manufacturer: BD Biosciences 564732
The A3 monoclonal antibody specifically binds to CD148. CD148 is a receptor-type tyrosine phosphatase that belongs to the receptor class 3 subfamily of the protein-tyrosine phosphatase family. CD148 is also known as Density-enhanced phosphatase 1 (DEP-1), Human protein tyrosine phosphatase- η (HPTP- η /HPTP-eta), or Protein tyrosine phosphatase receptor type J (PTPRJ). CD148 is a highly glycosylated type I transmembrane protein that is widely expressed on different cell types including monocytes, granulocytes, dendritic cells, thymocytes, T cells, B cells, NK cells, fibroblasts, and platelets. As a protein tyrosine phosphatase with receptor function, CD148 plays a role in regulating the signaling activities of various phosphorylated cellular proteins including the PDGF Receptor, catenins and Src family kinases. In the immune system, CD148 plays a role in regulating the activities of different cell types. For example, upon T cell activation, CD148 expression is upregulated by T cells. CD148 can subsequently dephosphorylate LAT and PLC-γsignaling protein s and thereby downregulate T cell signaling responses. Immobilized A3 antibody can reportedly augment the proliferation of anti-CD3 antibody-stimulated peripheral blood T cells in culture.
|DEP-1; DEP1; HPTP eta; HPTP-η; PTPRJ; R-PTP-eta; R-PTP-J; SCC1; p260|
|Activated human peripheral blood mononuclear cells|
|The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.|
|Alexa Fluor 647|
|Aqueous buffered solution containing BSA and ≤0.09% sodium azide.|
|Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok